The brain has its own waste disposal setup, and dementia can jam it. That's the part a team led by the Institute for Bioengineering of Catalonia went after, and the lab numbers are hard to ignore. Their answer is nanoscale compounds they call "supramolecular drugs." They don't work like conventional meds. What they do is engage the systems controlling the blood-brain barrier, the protective layer that tends to break down in dementia, and the aim is to get its transport machinery working again so amyloid-beta proteins, the ones closely tied to cognitive decline, can be cleared out properly. In the lab, toxic protein levels fell fast, up to 60 percent within an hour of treatment. Then came the longer animal work with aged mice: several doses left their cognitive performance looking like that of much younger animals. Plaques aren't the direct target here. What's being repaired is the brain's clearance capacity at the vascular and cellular level, and that reframing could matter for how neurodegenerative disease gets treated going forward. The study is by Chen, J., Battaglia, G., et al., published in 2026 in Signal Transduction and Targeted Therapy.
1w
The brain has its own waste disposal setup, and dementia can jam it. That's the part a team led by the Institute for Bioengineering of Catalonia went after, and the lab numbers are hard to ignore. Their answer is nanoscale compounds they call "supramolecular drugs." They don't work like conventional meds. What they do is engage the systems controlling the blood-brain barrier, the protective layer that tends to break down in dementia, and the aim is to get its transport machinery working again so amyloid-beta proteins, the ones closely tied to cognitive decline, can be cleared out properly. In the lab, toxic protein levels fell fast, up to 60 percent within an hour of treatment. Then came the longer animal work with aged mice: several doses left their cognitive performance looking like that of much younger animals. Plaques aren't the direct target here. What's being repaired is the brain's clearance capacity at the vascular and cellular level, and that reframing could matter for how neurodegenerative disease gets treated going forward. The study is by Chen, J., Battaglia, G., et al., published in 2026 in Signal Transduction and Targeted Therapy.
1w
No comments yet. Be the first!
Comments
No comments yet. Be the first!